These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15694016)

  • 1. Nonclassical retinoids and lung carcinogenesis.
    Dragnev KH; Petty WJ; Ma Y; Rigas JR; Dmitrovsky E
    Clin Lung Cancer; 2005 Jan; 6(4):237-44. PubMed ID: 15694016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin proteolysis as a retinoid cancer prevention mechanism.
    Dragnev KH; Freemantle SJ; Spinella MJ; Dmitrovsky E
    Ann N Y Acad Sci; 2001 Dec; 952():13-22. PubMed ID: 11795432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
    Sueoka N; Lee HY; Walsh GL; Hong WK; Kurie JM
    Cancer Res; 1999 Aug; 59(15):3838-44. PubMed ID: 10447003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.
    Kim HT; Kong G; Denardo D; Li Y; Uray I; Pal S; Mohsin S; Hilsenbeck SG; Bissonnette R; Lamph WW; Johnson K; Brown PH
    Cancer Res; 2006 Dec; 66(24):12009-18. PubMed ID: 17178900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Calu-1 human lung carcinoma cell growth in serum-free medium by retinoids: dependence on AP-1 activation, but not on retinoid response element activation.
    Wan H; Dawson MI; Hong WK; Lotan R
    Oncogene; 1997 Oct; 15(17):2109-18. PubMed ID: 9366527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoid targets in cancer therapy and chemoprevention.
    Dragnev KH; Petty WJ; Dmitrovsky E
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S150-6. PubMed ID: 14508093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.
    Song JI; Lango MN; Hwang JD; Drenning SD; Zeng Q; Lamph WW; Grandis JR
    Cancer Res; 2001 Aug; 61(15):5919-25. PubMed ID: 11479234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids.
    Sun SY; Kurie JM; Yue P; Dawson MI; Shroot B; Chandraratna RA; Hong WK; Lotan R
    Clin Cancer Res; 1999 Feb; 5(2):431-7. PubMed ID: 10037194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.
    Dragnev KH; Pitha-Rowe I; Ma Y; Petty WJ; Sekula D; Murphy B; Rendi M; Suh N; Desai NB; Sporn MB; Freemantle SJ; Dmitrovsky E
    Clin Cancer Res; 2004 Apr; 10(7):2570-7. PubMed ID: 15073138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
    Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
    Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors.
    Kim YH; Dohi DF; Han GR; Zou CP; Oridate N; Walsh GL; Nesbitt JC; Xu XC; Hong WK; Lotan R
    Cancer Res; 1995 Dec; 55(23):5603-10. PubMed ID: 7585641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
    Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
    J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted lung cancer therapies.
    Farmer G
    Nat Rev Drug Discov; 2004 Jul; 3(7):547-8. PubMed ID: 15272497
    [No Abstract]   [Full Text] [Related]  

  • 19. Retinoids and rexinoids in cancer prevention: from laboratory to clinic.
    Uray IP; Dmitrovsky E; Brown PH
    Semin Oncol; 2016 Feb; 43(1):49-64. PubMed ID: 26970124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
    Cras A; Politis B; Balitrand N; Darsin-Bettinger D; Boelle PY; Cassinat B; Toubert ME; Chomienne C
    Clin Cancer Res; 2012 Jan; 18(2):442-53. PubMed ID: 22142826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.